Herpes simplex thymidine kinase gene transfer is required for complete regression of murine colon adenocarcinoma

American Surgeon

Volumn 63, Issue 7, 1997, Pages 617-620

  Nielsen, Christopher S ^a   Moorman, Donald W ^a   Levy, John P ^b   Link Jr , Charles J ^b,c  

^a IOWA METHODIST MEDICAL CENTER   (United States)

^b Iowa Cancer Research Foundation   (United States)

^c Gene Therapy Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; GANCICLOVIR; THYMIDINE; THYMIDINE KINASE;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CELL PROLIFERATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; GENE; GENE TARGETING; GENE TRANSFER; HERPES SIMPLEX; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; SCINTIGRAPHY; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; CELL DIVISION; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, VIRAL; GENETIC VECTORS; HERPES SIMPLEX; MICE; MICE, INBRED STRAINS; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

EID: 0030917844     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Oliver S, Bubley G, Crumpacker C. Inhibition of HSV-transformed murine cells by nucleoside analogs 2′-NDG and 2′-nor-GMP. Virology 1985;145:84-93.
2. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res 1986;46:5276-81.
3. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990;80:297-300.
4. Elion G. The chemotherapeutic exploitation of virus-specified enzymes. Adv. Enzyme Regul 1980;18:53-66.
5. Ram Z, Culver K, Walbridge, S, et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1993;53:83-8.
6. Freeman S, Abboud C, Whartenby K, et al. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274-83.
7. Bi WL, Parysek L, Warnick P, et al. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 1993; 4:725-31.
8. Mesnil M, Piccoli C, Tiraby G, et al. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996;93:1831-5.
9. Caruso M, Panis Y, Gagandeep S, et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993;90:7024-8.
10. Short MP, Choi BC, Lee J, et al. Gene delivery to glioma cells in rat brain by grafting of a retroviral packaging cell line. J Neurosci Res 1990;27:427-39.
11. Link CJ, Kolb E, Muldoon R. Preliminary in vitro efficacy and toxicities studies of the herpes simplex thymidine kinase gene system for the treatment of breast cancer. Hybridoma 1995;14:143-7.
12. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986;6:2895-902.
13. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques 1989;7:980-8.
14. Oldfield EH, Ram Z, Culver K. Gene therapy for the treatment of brain tumors using intratumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 1993;4:39-69.
15. Link CJ, Moorman D, Seregina T. A Phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer. Hum Gene Ther 1996;7:1161-79.
16. Black ME, Newcomb, T, Wilson H, et al. Creation of drug specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci USA 1996;93:3525-9.